Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$6.1 million.

  • Rani Therapeutics Holdings' Net Cash Flow fell 246202.53% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137000.0, marking a year-over-year increase of 8028.78%. This contributed to the annual value of -$2.1 million for FY2024, which is 9003.93% up from last year.
  • Rani Therapeutics Holdings' Net Cash Flow amounted to -$6.1 million in Q3 2025, which was down 246202.53% from $105000.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' Net Cash Flow's 5-year high stood at $60.4 million during Q3 2021, with a 5-year trough of -$69.5 million in Q3 2022.
  • Its 5-year average for Net Cash Flow is -$3.6 million, with a median of -$2.4 million in 2024.
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Net Cash Flow soared by 165105.77% in 2021, and later tumbled by 246202.53% in 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Net Cash Flow (Quarter) stood at -$12.3 million in 2021, then surged by 98.28% to -$212000.0 in 2022, then surged by 520.75% to $892000.0 in 2023, then crashed by 158.18% to -$519000.0 in 2024, then plummeted by 1069.94% to -$6.1 million in 2025.
  • Its Net Cash Flow stands at -$6.1 million for Q3 2025, versus $105000.0 for Q2 2025 and $6.3 million for Q1 2025.